Shots:

• The companies initiate the clinical trial of A2a receptor antagonist- co-developed by Exscientia and Evotec utilizing Exscientia's AI-design platform- Centaur Chemist
• Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development
• The A2a receptor is currently in development for adult patients with advanced solid tumors and has the potential to show high selectivity for the targeted receptor

  Ref: Evotec | Image: Wikipedia